Dr. Rhonda Patrick

It's much easier to get FDA approval to do these sort of things in dogs than humans.

But it's like, you know, once you get to the dogs, you have humans that are like, of course, I want my dog to live longer.

And so they're going to, you know, start to approve those sort of therapies for dogs.

And then it's easier to then start them in humans.

So I think, again, AI is going to play a role in getting some of these gene therapies, you know, from bench side, from, you know, this preclinical data into humans and

All this is super exciting.

CRISPR is one company.

One of the directions, so gene therapy versus gene editing.

So gene editing would be CRISPR.

That's a technology that's used to change just like a single nucleotide of DNA, which can change the function of a gene.

So, for example, some people have, you know, these variations in our genes that make us not have them work as good.

Some people have diseases because of it, right?

Cystic fibrosis being one, right?

Muscular dystrophy, right?

Things like that where you have just a little one nucleotide or two nucleotide change in a gene and it completely alters the function.

So CRISPR can come in and actually change that gene.

So you can basically take someone who has a disease and completely wipe that disease out and reverse it so they don't have it anymore.

Or perhaps you can alter the DNA of a gene and make it work better.

Gene therapy is where you're basically just putting more of a gene there.

So let's say we have these longevity genes, for example, FOXO3 being one.